188 related articles for article (PubMed ID: 16479195)
1. The effect of different anticoagulants on thrombin generation.
Petros S; Siegemund T; Siegemund A; Engelmann L
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):131-7. PubMed ID: 16479195
[TBL] [Abstract][Full Text] [Related]
2. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
3. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin.
Gerotziafas GT; Dupont C; Spyropoulos AC; Hatmi M; Samama MM; Kiskinis D; Elalamy I
Thromb Haemost; 2009 Jul; 102(1):42-8. PubMed ID: 19572066
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R
Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943
[TBL] [Abstract][Full Text] [Related]
5. A laboratory method for parallel determination of platelet aggregation and thrombin generation.
Köstenberger M; Gallistl S; Cvirn G; Muntean W
Clin Lab; 2004; 50(1-2):41-8. PubMed ID: 15000219
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
7. Effect of substrate and fibrin polymerization inhibitor on determination of plasma thrombin generation in vitro.
Lau A; Berry LR; Mitchell LG; Chan AK
Thromb Res; 2007; 119(6):667-77. PubMed ID: 16793122
[TBL] [Abstract][Full Text] [Related]
8. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
[TBL] [Abstract][Full Text] [Related]
9. Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Rousseau A; Van Dreden P; Mbemba E; Elalamy I; Larsen A; Gerotziafas GT
Thromb Res; 2015 Dec; 136(6):1273-9. PubMed ID: 26489727
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of factor IIa inhibitors on the endogenous thrombin potential.
Beilfuss A; Grandoch M; Wenzel F; Hohlfeld T; Schrör K; Weber AA
Ther Drug Monit; 2008 Dec; 30(6):740-3. PubMed ID: 18824953
[TBL] [Abstract][Full Text] [Related]
11. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
[TBL] [Abstract][Full Text] [Related]
12. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
13. Measurement of maximum thrombin generation capacity in blood and plasma using the thrombin generation assay (THROGA).
Nowak G; Lange U; Wiesenburg A; Bucha E
Semin Thromb Hemost; 2007 Jul; 33(5):508-14. PubMed ID: 17629848
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors.
Taketomi T; Szlam F; Vinten-Johansen J; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2007 Dec; 18(8):761-7. PubMed ID: 17982317
[TBL] [Abstract][Full Text] [Related]
15. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
Graff J; von Hentig N; Misselwitz F; Kubitza D; Becka M; Breddin HK; Harder S
J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
[TBL] [Abstract][Full Text] [Related]
16. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
[TBL] [Abstract][Full Text] [Related]
17. Biochemistry and pharmacology of low molecular weight heparin.
Rosenberg RD
Semin Hematol; 1997 Oct; 34(4 Suppl 4):2-8. PubMed ID: 9399404
[No Abstract] [Full Text] [Related]
18. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of thrombin inactivation by immobilized heparin.
Byun Y; Jacobs HA; Kim SW
J Biomed Mater Res; 1996 Apr; 30(4):423-7. PubMed ID: 8847350
[TBL] [Abstract][Full Text] [Related]
20. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
